8840 related articles for article (PubMed ID: 12380046)
21. Human melanocyte senescence and melanoma susceptibility genes.
Bennett DC
Oncogene; 2003 May; 22(20):3063-9. PubMed ID: 12789281
[TBL] [Abstract][Full Text] [Related]
22. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
[TBL] [Abstract][Full Text] [Related]
23. Familial cutaneous melanoma.
Hansson J
Adv Exp Med Biol; 2010; 685():134-45. PubMed ID: 20687502
[TBL] [Abstract][Full Text] [Related]
24. [The genes disposing to malignant melanoma--a systematic review].
Wadt KA; Drzewiecki KT; Gerdes AM
Ugeskr Laeger; 2012 Feb; 174(8):493-7. PubMed ID: 22348671
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
[TBL] [Abstract][Full Text] [Related]
26. A piece of the melanoma puzzle.
Goldstein AM; Tucker MA
J Natl Cancer Inst; 2005 Oct; 97(20):1486-7. PubMed ID: 16234555
[No Abstract] [Full Text] [Related]
27. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
28. Genetics of melanoma susceptibility.
Ghiorzo P; Scarrà GB
Forum (Genova); 2003; 13(2):114-22; quiz 187. PubMed ID: 14732879
[TBL] [Abstract][Full Text] [Related]
29. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.
Soufir N; Lacapere JJ; Bertrand G; Matichard E; Meziani R; Mirebeau D; Descamps V; Gérard B; Archimbaud A; Ollivaud L; Bouscarat F; Baccard M; Lanternier G; Saïag P; Lebbé C; Basset-Seguin N; Crickx B; Cave H; Grandchamp B
Br J Cancer; 2004 Jan; 90(2):503-9. PubMed ID: 14735200
[TBL] [Abstract][Full Text] [Related]
30. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.
Ghiorzo P; Pastorino L; Pizzichetta MA; Bono R; Queirolo P; Talamini R; Annessi G; Bruno W; Nasti S; Gargiulo S; Battistuzzi L; Sini MC; Palmieri G; Scarrà GB;
Melanoma Res; 2009 Jun; 19(3):142-5. PubMed ID: 19339902
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
FitzGerald MG; Harkin DP; Silva-Arrieta S; MacDonald DJ; Lucchina LC; Unsal H; O'Neill E; Koh J; Finkelstein DM; Isselbacher KJ; Sober AJ; Haber DA
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8541-5. PubMed ID: 8710906
[TBL] [Abstract][Full Text] [Related]
32. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
33. The fibroblast growth factor-2 is not essential for melanoma formation in a transgenic mouse model.
Ackermann J; Beermann F
Pigment Cell Res; 2005 Aug; 18(4):315-9. PubMed ID: 16029424
[TBL] [Abstract][Full Text] [Related]
34. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families.
Chaudru V; Chompret A; Bressac-de Paillerets B; Spatz A; Avril MF; Demenais F
J Natl Cancer Inst; 2004 May; 96(10):785-95. PubMed ID: 15150307
[TBL] [Abstract][Full Text] [Related]
35. Genetic testing for melanoma.
Kefford R; Bishop JN; Tucker M; Bressac-de Paillerets B; Bianchi-Scarrá G; Bergman W; Goldstein A; Puig S; Mackie R; Elder D; Hansson J; Hayward N; Hogg D; Olsson H;
Lancet Oncol; 2002 Nov; 3(11):653-4. PubMed ID: 12424065
[No Abstract] [Full Text] [Related]
36. Advances in malignant melanoma: genetic insights from mouse and man.
Kabbarah O; Chin L
Front Biosci; 2006 Jan; 11():928-42. PubMed ID: 16146783
[TBL] [Abstract][Full Text] [Related]
37. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
38. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma.
Pho L; Grossman D; Leachman SA
Curr Opin Oncol; 2006 Mar; 18(2):173-9. PubMed ID: 16462187
[TBL] [Abstract][Full Text] [Related]
39. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
40. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.
Grafström E; Egyházi S; Ringborg U; Hansson J; Platz A
Clin Cancer Res; 2005 Apr; 11(8):2991-7. PubMed ID: 15837753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
